It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 3.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Cathie Wood increased her Meta position in Q3 2025, adding about 791,000 shares. The move came after two quarters of selling, ...

India's GenAI infrastructure is being built, but can a public-private partnership outpace the trillion-dollar budgets of US ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...